English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Mesial temporal lobe epilepsy (MTLE) stands out among the different types of epilepsy due to its prevalence and the high rate of resistance to the treatment with antiepileptic drugs (AEDs). Because of the challenge to predict which patients will respond to drug treatments, alternative therapies to seizures, such as epilepsy surgery, may take many years to be indicated. Thereby, the search for new biomarkers, capable of predicting which pateitns witll be AED resistance is necessary. The metabolomic approach has many advantages over other molecular techniques, such as greater proximity of the metabolites to the phenotype and high sensitivity and specificity in the detection of these analytes. Therefore, the main objective of the present sutidy is to use metabolomics to find biomarkers of AED resistance in patients with MTLE.

Metabolomic analysis of blood plasma from patients with mesial temporal lobe epilepsy: a search for biomarkers of drug resistance